This area is reserved for registered users. Please register or login.

Efficacy and Safety of Gazyvaro▼ for Treatment of Rituximab-Refractory Follicular Lymphoma

Roche is pleased to announce that Gazyvaro (obinutuzumab) is available in Ireland for the treatment of patients with previously treated follicular lymphoma (FL). Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to six months after treatment with rituximab or a rituximab-containing regimen.1 There was a total of 787 cases of non-Hodgkin’s lymphoma (NHL) diagnosed in Ireland in 2013, of which 23.6% (186 cases) were represented by subtype FL.2 Response rates to rituximab-based treatment, the current standard of care in FL,…